medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2022, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2022; 31 (1)

Leukocyte adhesion deficiency

Cano PRY, Berrón PL, Espinosa-Padilla SE

Language: Spanish
References: 25
Page: 21-26
PDF size: 273.93 Kb.


ABSTRACT

Leukocyte adhesion deficiency (LAD) is a defect in cell adhesion molecules that leads to clinical syndromes. During inflammation, leukocytes play a key role in maintaining tissue homeostasis by killing pathogens and removing damaged tissue. Leukocytes migrate to the site of inflammation by crawling over and through the wall of the blood vessels into the tissue. Leukocyte adhesion deficiencies (i.e., LAD-I, -II, and LAD-I/variant, the latter also known as LAD-III) are caused by defects in leukocyte adhesion to the blood vessel wall, due to mutations in genes, encoding β2 integrin (ITGB2), a GDP-fucose transport protein (SLC35C1) and kindlin-3 (FERMT3), respectively.


REFERENCES

  1. Ley K, Luadanna V, Cybulsky MI et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007; 7: 678-689.

  2. Etzioni A. Leukocyte adhesion deficiencies: molecular basis, clinical findings, and therapeutic options: base molecular, clinical findings and therapeutic options. Adv Exp Med Biol. 2007; 601: 51-60.

  3. Mc Ever RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol. 2002; 14 (5): 581-586.

  4. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction form and prerequisite for adhesion through integrins. Cell. 1991; 65 (5): 859-873.

  5. Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol. 2009; 27 (1): 339-362.

  6. Etzioni A. Genetic etiologies of leukocyte adhesion defects. Curr Opin Immunol. 2009; 21 (5): 481-486.

  7. Van de Vijver E, van den Berg TK, Kuijpers TW. Leukocyte adhesion deficiencies. Hemato Oncol Clin North Am. 2013; 27: 101-116.

  8. Parvaneh N, Mamishi S, Rezaei A et al. Characterization of 11 new cases of leukocyte adhesion deficiency type 1 with seven novel mutations in the ITGB2 gene. J Clin Immunol. 2010; 30 (5): 756-760.

  9. Cox DP, Weathers DR. Leukocyte adhesion deficiency type 1: an important consideration in the clinical differential diagnosis of prepubertal periodontitis. A case report and review of the literature. Oral Surg Oral Med Oral Pahol Oral Radiol Endod. 2008; 105 (1): 86-90.

  10. Movahedi MA, Entezari N, Pourpak Z et al. Clinical and laboratory findings in Iranian patients with leukocyte adhesion deficiency (study of 15 cases). J Clin Immunol. 2007; 27 (3): 302-307.

  11. Almarza Novoa E, Kasbekar S, Thrasher AJ et al. Leukocyte adhesion deficiency-I: A comprehensive review of all published cases. J Allergy Clin Immunol Pract. 2018; 6 (4): 1418-1420.

  12. Tokunaga M, Miyamura K. Successful nonmyeloablative bone marrow transplantation for leukocyte adhesion deficiency type I from and unrelated donor. Int J Hematol. 2007; 86 (1): 91-95. 25. Justiz Vaillant AA, Ahmad F. Leukocyte Adhesion Deficiency. Stat Pearls. 2021.

  13. Gazit Y, Mory A, Etzioni A et al. Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature. J Clin Immunol. 2010; 30 (2): 308-313.

  14. Fischer A, Lisowska-Grospierre B, Anderson DC et al. Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodefic Rev. 1988; 198; 1 (1): 39-54.

  15. Justiz Vaillant AA, Qurie A. Immunodeficiency. StatPearls: 2020.

  16. Roberts MW, Atkinson JC. Oral manifestations associated with leukocyte adhesion deficiency: a five-year case study. Pediatric Dent. 1990; 12 (2): 107-111.

  17. Marquardt T, Luhn K, Srikrishna G et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood. 1999; 94 (12): 3976-3985.

  18. Wild MK, Luhn K, Marquardt T et al. Leukocyte adhesion deficiency II: therapy and genetic defect. Cells Tissues Organs. 2002; 172 (3): 161-173.

  19. McDowall A, Inwald D, Leitinger B et al. A novel form of integrin dysfunction involving beta1, beta2 and beta 3 integrins. J Clin Invest. 2003; 111 (1): 51-60.

  20. Thomas C, Le Deist F, Cavazzana-Calvo M, Benkerrou M et al. Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency. Blood. 1995; 86 (4): 1629-1635.

  21. Moutsopoulos NM, Zerbe CS, Wild T et al. Interleukin-12 and Interlukin-23 Blockade in Leukocyte Adhesion Deficiency Type 1. N Engl J Med. 2017; 376 (12): 1141-1146.

  22. Weening RS, Bredius RG, Vomberg PP et al. Recombinant human interferon-gamma treatment in severe leucocyte adhesion deficiency. Eur J Pediatrics. 1992; 151 (2): 103-107.

  23. Saultier P, Szepetowski S, Canault M et al. Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation. Hematologica. 2018; 103 (6): 264-267.

  24. Yamazaki-Nakashimada M, Maravillas-Montero JL, Berrón-Ruiz L et al. Successful adjunctive immunoglobulin treatment in patients affected by leukocyte adhesion deficiency type I (LAD-1). Immunol Res. 2015; 61 (3): 260-268.

  25. Justiz VAA, Ahmad F. Leukocyte Adhesion Deficiency. Stat Pearls. 2021.




2020     |     www.medigraphic.com